Shared Care Agreements

AMBER with SHARED CARE medicines require significant monitoring and to qualify must be designated so by the BSW APC. Primary care prescribers are advised not to take on prescribing of these medicines unless they have been adequately informed in writing (by letter or via secure email) of their responsibilities with regards to monitoring, side effects and interactions and are happy to take on the prescribing responsibility. A copy of the locally approved SCA should accompany the request. Primary care prescribers should reply to the request as soon as practicable if they are unable to support shared care (in writing or via secure email) and then arrange the transfer of care as necessary. This will ensure absolute clarity as to who is taking over the prescribing and any associated monitoring responsibilities.

Sharing of care assumes communication between the specialist, primary care prescriber and patient. The intention to share care is usually explained to the patient by the prescriber initiating treatment. It is important that patients are consulted about treatment and are in agreement. Where appropriate, patients should remain under regular follow-up in secondary care, where it is expected that the patient’s overall response to treatment and need for continued treatment will be monitored.

The APC are working to review and align Traffic Light Statuses (TLS) and SCAs across BSW. Where differences in TLS and SCAs exist, clinicians should refer to the agreement for their locality.

A full list of SCAs agreed for BSW are listed below (A-Z) and are also available in the relevant drug entry or section on the formulary website bswformulary.nhs.uk

The formulary and APC websites remain under development. For further information or to report inaccuracies/feedback email bswicb.formulary@nhs.net